Plain-English translation of NCT06683378 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Parkinson's Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether implanting autologous peripheral nerve tissue — a small piece of nerve taken from your own leg — into targeted areas of your brain during deep brain stimulation surgery can help repair brain cells and improve both thinking and movement problems in Parkinson's disease. You would receive this implant at the same time you have your standard deep brain stimulation surgery, so it does not require a separate operation. Researchers want to see if the treatment is safe and whether it helps with memory, cognition, motor symptoms, and quality of life.
Parkinson's disease damages brain cells that control movement and thinking. Deep brain stimulation surgery is already a standard treatment, but doctors are exploring whether adding nerve tissue from your own body might help repair damaged brain areas and improve both motor and cognitive symptoms that current treatments don't fully address.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will undergo one surgery where your deep brain stimulation device is implanted and, at the same time, a small piece of nerve tissue from your leg (the sural nerve) is implanted into a specific area of your brain. After surgery, you will return for follow-up visits at 2 weeks, 6 months, 12 months, and 24 months to have your thinking, movement, daily activities, and quality of life assessed through tests and questionnaires. The entire study participation lasts about 2 years.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States